Cytex Therapeutics Inc.
04/29/2024 | Press release | Distributed by Public on 04/29/2024 13:08
Annual Report by Private Issuer - Form C-AR
| FORM C |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
OMB APPROVAL |
|
|
OMB Number: ####-#### Estimated average burden hours per response: ##.# |
Form C: Filer Information
| Filer CIK: |
0001943908
|
| Filer CCC: |
XXXXXXXX
|
| Period: |
12-31-2023
|
| Is this a LIVE or TEST Filing? | LIVE TEST |
| Is this an electronic copy of an official filing submitted in paper format in connection with a hardship exemption? | |
| Would you like a Return Copy? |
Submission Contact Information
| Name: |
|
| Phone Number: |
|
| Contact E-Mail Address: |
|
| Notify via Filing Website only? |
Form C: Issuer Information
Issuer Information
| Name of Issuer: |
Cytex Therapeutics, Inc.
|
Legal Status of Issuer:
| Form: |
Corporation
|
| Jurisdiction of Incorporation/Organization: |
DELAWARE
|
| Date of Incorporation/Organization: |
07-21-2006
|
Physical Address of Issuer:
| Address 1: |
2609 N. Duke Street, Suite 303A
|
| City: |
Durham
|
| State/Country: |
NORTH CAROLINA
|
| Mailing Zip/Postal Code: |
27704
|
| Website of Issuer: |
http://www.cytexortho.com
|
Form C: Annual Report Disclosure Requirements
Annual Report Disclosure Requirements
| Current Number of Employees: |
8
|
| Total Assets Most Recent Fiscal Year-end: |
385279.00
|
| Total Assets Prior Fiscal Year-end: |
719644.00
|
| Cash and Cash Equivalents Most Recent Fiscal Year-end: |
170770.00
|
| Cash and Cash Equivalents Prior Fiscal Year-end: |
474993.00
|
| Accounts Receivable Most Recent Fiscal Year-end: |
57591.00
|
| Accounts Receivable Prior Fiscal Year-end: |
47914.00
|
| Short-term Debt Most Recent Fiscal Year-end: |
192787.00
|
| Short-term Debt Prior Fiscal Year-end: |
193580.00
|
| Long-term Debt Most Recent Fiscal Year-end: |
575135.00
|
| Long-term Debt Prior Fiscal Year-end: |
490492.00
|
| Revenue/Sales Most Recent Fiscal Year-end: |
1284927.00
|
| Revenue/Sales Prior Fiscal Year-end: |
1052219.00
|
| Cost of Goods Sold Most Recent Fiscal Year-end: |
858498.00
|
| Cost of Goods Sold Prior Fiscal Year-end: |
731921.00
|
| Taxes Paid Most Recent Fiscal Year-end: |
-10845.00
|
| Taxes Paid Prior Fiscal Year-end: |
14219.00
|
| Net Income Most Recent Fiscal Year-end: |
-1214922.00
|
| Net Income Prior Fiscal Year-end: |
-621726.00
|
Form C: Signature
Signature
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.| Issuer: |
Cytex Therapeutics, Inc.
|
| Signature: |
Bradley T. Estes
|
| Title: |
CEO and Director
|
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.
| Signature: |
Bradley T. Estes
|
| Title: |
CEO and Director
|
| Date: |
04-29-2024
|
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.
| Signature: |
Christine Estes
|
| Title: |
Director of Business and Finance, Secretary and Treasurer
|
| Date: |
04-29-2024
|
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.
| Signature: |
Farshid Guilak
|
| Title: |
Board Chairman
|
| Date: |
04-29-2024
|
Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100-503), this Form C has been signed by the following persons in the capacities and on the dates indicated.
| Signature: |
David Nolan
|
| Title: |
Director
|
| Date: |
04-29-2024
|